We could program cells to produce a given amount of a particular protein over a specified time period?
We can design cellular software – in the form of messenger RNA – that allows people to make their own vaccines and medicines in a controllable and reversible way.
Founded in 2010 by Flagship Pioneering, Moderna (NASDAQ: MRNA) is focused on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines, a new class of potential medicines that directs the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit for both patients and healthy individuals.
Moderna is creating potential mRNA medicines for a wide range of diseases and conditions which currently include infectious diseases, oncology, rare genetic diseases, and cardiovascular diseases. Moderna is developing these potential medicines independently and through strategic alliances with collaborators, including AstraZeneca, Merck, and Vertex Pharmaceuticals, as well as the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), and the Bill & Melinda Gates Foundation.
Latest Press from Moderna
- Moderna to Present Data From Two of Its Prophylactic mRNA Vaccines at IDWeek 2019 10.02.2019
- Moderna Announces Open IND for Propionic Acidemia Program (mRNA-3927) 09.30.2019
- Moderna Announces mRNA Immunotherapy Research Collaboration with Harvard University 09.26.2019
- Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944) 09.12.2019
- Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials 09.12.2019
- Moderna Appoints Tracey Franklin as Chief Human Resources Officer 09.04.2019